Pacira Pharmaceuticals (PCRX): שווי כולל של נכסי החברה

The chart-confirmed market price of Pacira BioSciences (PCRX) total assets is 1394.29. The current trend is clouded by the threat of expansion from Exparel generics, which could crash future revenues. The business relies on strict adherence to temperature controls during the delivery of analgesics to clinics. Meanwhile, management is effectively defending intellectual property and expanding its share in the non-narcotic drug segment.

This indicator measures the aggregate value of Pacira BioSciences (PCRX) resources, calculated inversely via ROA to isolate random market fluctuations from systemic balance sheet transformations. An analysis of balance sheet assets allows for an assessment of how the financial base of Pacira BioSciences aligns with the scale of Exparel's integration into surgical protocols, confirming the fundamental stability of the painless recovery ecosystem.